Citigroup downgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a neutral rating in a research note issued to investors on Friday, MarketBeat reports. The firm currently has $380.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $480.00.
A number of other equities research analysts have also weighed in on the stock. J P Morgan Chase & Co restated a hold rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, November 28th. BTIG Research reduced their price objective on shares of Regeneron Pharmaceuticals from $520.00 to $480.00 and set a buy rating for the company in a research report on Tuesday, November 28th. BMO Capital Markets set a $444.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a hold rating in a research report on Monday, November 27th. Evercore ISI reduced their price objective on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an outperform rating for the company in a research report on Thursday, November 16th. Finally, Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, November 14th. Two equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $467.84.
Shares of Regeneron Pharmaceuticals (NASDAQ REGN) opened at $378.37 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07. Regeneron Pharmaceuticals has a fifty-two week low of $340.09 and a fifty-two week high of $543.55. The firm has a market cap of $40,650.00, a PE ratio of 32.33, a P/E/G ratio of 1.47 and a beta of 1.53.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. During the same quarter in the prior year, the business posted $3.13 EPS. The firm’s revenue was up 23.0% compared to the same quarter last year. analysts expect that Regeneron Pharmaceuticals will post 13.55 earnings per share for the current fiscal year.
In other news, Director Charles A. Baker sold 2,000 shares of the stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the transaction, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Robert E. Landry sold 663 shares of the stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $498.60, for a total transaction of $330,571.80. Following the transaction, the senior vice president now directly owns 10,099 shares of the company’s stock, valued at $5,035,361.40. The disclosure for this sale can be found here. Insiders have sold a total of 4,163 shares of company stock valued at $1,943,072 over the last three months. Insiders own 10.80% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in REGN. Harding Loevner LP boosted its holdings in Regeneron Pharmaceuticals by 589.2% in the 3rd quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock worth $286,619,000 after buying an additional 3,131,966 shares during the period. Janus Henderson Group PLC boosted its holdings in Regeneron Pharmaceuticals by 15,495.4% in the 2nd quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock worth $767,637,000 after buying an additional 1,552,948 shares during the period. Jennison Associates LLC boosted its holdings in Regeneron Pharmaceuticals by 74.1% in the 2nd quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock worth $634,977,000 after buying an additional 550,247 shares during the period. FMR LLC boosted its holdings in Regeneron Pharmaceuticals by 6.3% in the 2nd quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after buying an additional 416,192 shares during the period. Finally, Old Mutual Global Investors UK Ltd. boosted its holdings in Regeneron Pharmaceuticals by 500,446.2% in the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 325,355 shares of the biopharmaceutical company’s stock worth $145,472,000 after buying an additional 325,290 shares during the period. 66.67% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Citigroup Lowers Regeneron Pharmaceuticals (REGN) to Neutral” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://ledgergazette.com/2017/12/05/citigroup-lowers-regeneron-pharmaceuticals-regn-to-neutral.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.